BioCryst Pharmaceuticals (NASDAQ:BCRX) Earns “Outperform” Rating from Royal Bank of Canada
Royal Bank of Canada reissued their outperform rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) in a report published on Friday,Benzinga reports. The firm currently has a $11.00 price target on the biotechnology company’s stock. BCRX has been the subject of a number of other research reports. Needham & Company LLC reissued a […]
Royal Bank of Canada reissued their outperform rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) in a report published on Friday,Benzinga reports. The firm currently has a $11.00 price target on the biotechnology company’s stock. BCRX has been the subject of a number of other research reports. Needham & Company LLC reissued a […]